This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Candiani, C. Articles by Colombatti, M. Search for Related Content PubMed PubMed Citation Articles by Candiani, C. Articles by Colombatti, M.

Blocking Effect of Human Serum but not of Cerebrospinal Fluid on Ricin A Chain Immunotoxin Potentiation by Monensin or Carrier Protein-Monensin Conjugates¹

Istituto di Scienze Immunologiche [C. C., A. F., R. C., M. P., C. A., G. T., M. C.] and Istituto di Farmacologia [G. B.], University of Verona, Policlinico Borgo Roma, 37134 Verona, Italy

The potentiation of monoclonal antibody/ligand toxin (immunotoxin) cytotoxicity by the ionophore monensin (Mo) or by human serum albumin-monensin (HSA-Mo) conjugates was investigated. Since disulfide cross-linked HSA-Mo (HSA-SPDP-Mo) is rapidly inactivated by human serum (M. Colombatti et al., Cancer Res., 50: 1385–1391, 1990), we synthesized thioether cross-linked HSA-Mo conjugates (HSA-SIA-Mo). HSA-SIA-Mo is resistant to treatment with reducing agents (e.g., glutathione, dithiothreitol) and shows potentiating activity identical to that of Mo or of HSA-SPDP-Mo, enhancing immunotoxin (IT) cytotoxicity 45-35,000-fold.

Human leukemic and tumor cell lines are highly sensitive to treatment with IT in combination with Mo, HSA-SPDP-Mo, or HSA-SIA-Mo (concentration required to inhibit protein synthesis by 50%, 10^–10-2.5 x 10^–13 M).

IT potentiation by both types of HSA-Mo conjugates, however, is inhibited by whole human serum. In contrast, human cerebrospinal fluid has no effect on the potentiation of IT by Mo or HSA-Mo conjugates. The serum blocking factors reside mostly in a M_r 40,000–90,000 protein fraction. Serum components of low molecular weight (<10,000) show no detectable effect upon the stability of HSA-Mo conjugates.

The toxicity of HSA-SIA-Mo in vivo was investigated by intrathecal injections in rats. Concentrations of up to 60 µg/kg can be injected into the brain with only transient neurological sequelae.

We therefore conclude that if the systemic delivery of HSA-Mo conjugates for the potentiation of ricin A chain-IT presents some limitations due to the blocking effect of serum, the application of HSA-Mo conjugates in combination with ricin A chain-IT for regional tumor therapy in the brain appears more promising.

¹ This work was supported in part by grants from CNR (PF Ingegneria Genetica, PF Biotecnologie e Biostrumentazione), Associazione Italiana per la Ricerca sul Cancro, M.P.I. 40% Aspetti Clinico-Sperimentali della Risposta Immune, M.S. Progetto AIDS, and Associazione per la promozione delle Ricerche Biomediche.

² R. C. is a recipient of an AIRC Fellowship.

³ To whom requests for reprints should be addressed.

Received 7/15/91. Accepted 11/ 5/91.

This article has been cited by other articles:

				R. Chignola, C. Anselmi, M. D. Serra, A. Franceschi, G. Fracasso, M. Pasti, E. Chiesa, J. M. Lord, G. Tridente, and M. Colombatti Self-potentiation of Ligand-Toxin Conjugates Containing Ricin A Chain Fused with Viral Structures J. Biol. Chem., October 6, 1995; 270(40): 23345 - 23351. [Abstract] [Full Text] [PDF]